Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Gastrointest Liver Physiol ; 296(4): G923-30, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19164486

ABSTRACT

P2Y receptors have been reported to modulate gastrointestinal functions. The newest family member is the nucleotide-sugar receptor P2Y14. P2ry14 mRNA was detected throughout the rat gut, with the highest level being in the forestomach. We investigated the role of the receptor in stomach motility using cognate agonists and knockout (KO) mice. In rat isolated forestomach, 100 microM UDP-glucose and 100 muM UDP-galactose both increased the baseline muscle tension (BMT) by 6.2+/-0.6 and 1.6+/-0.6 mN (P<0.05, n=3-4), respectively, and the amplitude of contractions during electrical field stimulation (EFS) by 3.7+/-1.7 and 4.3+/-2.5 mN (P<0.05, n=3-4), respectively. In forestomach from wild-type (WT) mice, 100 microM UDP-glucose increased the BMT by 1.0+/-0.1 mN (P<0.05, n=6) but this effect was lost in the KO mice (change of -0.1+/-0.1 mN, n=6). The 100 microM UDP-glucose also increased the contraction amplitude during EFS in this tissue from the WT animals (0.9+/-0.4 mN, P < 0.05, n=6) but not from the KO mice (0.0+/-0.2 mN, n=6). In vivo, UDP-glucose at 2,000 mg/kg ip reduced gastric emptying in rats by 49.7% (P<0.05, n=4-6) and in WT and KO mice by 56.1 and 66.2%, respectively (P<0.05, n=7-10) vs. saline-treated control animals. There was no significant difference in gastric emptying between WT and KO animals receiving either saline or d-glucose. These results demonstrate a novel function of the P2Y14 receptor associated with contractility in the rodent stomach that does not lead to altered gastric emptying after receptor deletion and an ability of UDP-glucose to delay gastric emptying without involving the P2Y14 receptor.


Subject(s)
Gastric Emptying/drug effects , Receptors, Purinergic P2/metabolism , Uridine Diphosphate Glucose/pharmacology , Animals , Dose-Response Relationship, Drug , Gene Expression Regulation/physiology , Lac Operon/genetics , Lac Operon/physiology , Mice , Mice, Knockout , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Receptors, Purinergic P2/genetics , Receptors, Purinergic P2Y , Uridine Diphosphate Galactose/pharmacology
2.
J Pharmacol Exp Ther ; 312(2): 718-25, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15475592

ABSTRACT

Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists have been shown to have significant therapeutic benefits such as desirable glycemic control in type 2 diabetic patients; however, these agents may cause fluid retention in susceptible individuals. Since PPARgamma is expressed selectively in distal nephron epithelium, we studied the mechanism of PPARgamma agonist-induced fluid retention using male Sprague-Dawley rats treated with either vehicle or GI262570 (farglitazar), a potent PPARgamma agonist. GI262570 (20 mg/kg/day) induced a plasma volume expansion. The plasma volume expansion was accompanied by a small but significant decrease in plasma potassium concentration. Small but significant increases in plasma sodium and chloride concentrations were also observed. These changes in serum electrolytes suggested an activation of the renal mineralocorticoid response system; however, GI262570-treated rats had lower plasma levels of aldosterone compared with vehicle-treated controls. mRNA levels for a group of genes involved in distal nephron sodium and water absorption are changed in the kidney medulla with GI262570 treatment. In addition, due to a possible rebound effect on epithelial sodium channel (ENaC) activity, a low dose of amiloride did not prevent GI262570-induced fluid retention. On the contrary, the rebound effect after amiloride treatment potentiated GI262570-induced plasma volume expansion. This is at least partially due to a synergistic effect of GI262570 and the rebound from amiloride treatment on ENaCalpha expression. In summary, our current data suggest that GI262570 can increase water and sodium reabsorption in distal nephron by stimulating the ENaC and Na,K-ATPase system. This may be an important mechanism for PPARgamma agonist-induced fluid retention.


Subject(s)
Electrolytes/metabolism , Kidney Tubules, Distal/metabolism , Nephrons/metabolism , Oxazoles/pharmacology , PPAR gamma/agonists , Tyrosine/analogs & derivatives , Tyrosine/pharmacology , Water/metabolism , Actins/biosynthesis , Aldosterone/blood , Amiloride/pharmacology , Animals , Blood Volume/drug effects , Diuretics/pharmacology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelial Sodium Channels , Gene Expression/drug effects , Kidney Medulla/drug effects , Kidney Medulla/metabolism , Kidney Tubules, Distal/cytology , Kidney Tubules, Distal/drug effects , Male , Nephrons/cytology , Nephrons/drug effects , RNA/biosynthesis , RNA/isolation & purification , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Sodium/metabolism , Sodium Channels/biosynthesis , Sodium Channels/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...